Literature DB >> 14716825

Expression of estrogen receptor beta in human colorectal cancer.

Li-Qun Xie1, Jie-Ping Yu, He-Sheng Luo.   

Abstract

AIM: To determine the expression of estrogen receptor (ER) beta in Chinese colorectal carcinoma (CRC) patients.
METHODS: ERbeta expression in CRC was investigated by immunohistochemical staining of formalin-fixed, paraffin-embedded tissue sections from 40 CRCs, 10 colonic adenomas, and 10 normal colon mucosa biopsies. The percentage of positive cells was recorded, mRNA expression of ERalpha and ERbeta in 12 CRC tissues and paired normal colon tissues were detected by RT-PCR.
RESULTS: Positive ER immunoreactivity was present in part of normal epithelium of biopsy (2/10), adenomas (3/10), and the sections of CRC tissue, most of them were nuclear positive. In CRCs, nuclear ERbeta immunoreactivity was detected in over 10% of the cancer cells in 57.5% of the cases and was always associated with cytoplasmic immunoreactivity. There was no statistical significance between ERbeta positive and negative groups in regard to depth of invasion and nodal metastases. Of the 12 CRC tissues and paired normal colon tissues, the expression rate of ERalpha mRNA in CRC tissue and corresponding normal colon tissue was 25% and 16.6%, respectively. ERbeta mRNA was expressed in 83.3% CRC tissue and 91.7% paired normal colon tissue, respectively. There was no significant difference in ERbeta mRNA level between CRC tissues and paired normal colon tissues.
CONCLUSION: A large number of CRCs are positive for ERbeta, which can also be detected in normal colonic epithelia. There is a different localization of ERbeta immunoreactivity among normal colon mucosae, adenomas and CRCs. ERalpha and ERbeta mRNA can be detected both in CRC tissue and in corresponding normal colon tissue. A post-transcriptional mechanism may account for the decrease of ERbeta protein expression in CRC tissues.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14716825      PMCID: PMC4717006          DOI: 10.3748/wjg.v10.i2.214

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

Review 1.  Hormone replacement therapy (HRT)--risks and benefits.

Authors:  E Barrett-Connor; C A Stuenkel
Journal:  Int J Epidemiol       Date:  2001-06       Impact factor: 7.196

Review 2.  Hormone replacement therapy for menopausal women.

Authors:  K S Moghissi
Journal:  Compr Ther       Date:  2000

3.  Obesity, gender, and colon cancer.

Authors:  E Giovannucci
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

4.  Oestrogen-induced apoptosis in colonocytes expressing oestrogen receptor beta.

Authors:  Y Qiu; C E Waters; A E Lewis; M J S Langman; M C Eggo
Journal:  J Endocrinol       Date:  2002-09       Impact factor: 4.286

5.  Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue.

Authors:  E Leygue; H Dotzlaw; P H Watson; L C Murphy
Journal:  Cancer Res       Date:  1999-03-15       Impact factor: 12.701

6.  Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines.

Authors:  Dan Tong; Eva Schuster; Michael Seifert; Klaus Czerwenka; Sepp Leodolte; Robert Zeillinger
Journal:  Breast Cancer Res Treat       Date:  2002-02       Impact factor: 4.872

7.  Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis.

Authors:  F Grodstein; P A Newcomb; M J Stampfer
Journal:  Am J Med       Date:  1999-05       Impact factor: 4.965

8.  Estrogen receptor beta is expressed in human colorectal adenocarcinoma.

Authors:  D Witte; M Chirala; A Younes; Y Li; M Younes
Journal:  Hum Pathol       Date:  2001-09       Impact factor: 3.466

9.  Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern.

Authors:  E Enmark; M Pelto-Huikko; K Grandien; S Lagercrantz; J Lagercrantz; G Fried; M Nordenskjöld; J A Gustafsson
Journal:  J Clin Endocrinol Metab       Date:  1997-12       Impact factor: 5.958

10.  Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation.

Authors:  P A Konstantinopoulos; A Kominea; G Vandoros; G P Sykiotis; P Andricopoulos; I Varakis; G Sotiropoulou-Bonikou; A G Papavassiliou
Journal:  Eur J Cancer       Date:  2003-06       Impact factor: 9.162

View more
  16 in total

1.  Potential value of estrogen receptor beta expression in colorectal carcinoma: interaction with apoptotic index.

Authors:  Hosam Ghazy Elbanna; Mohamed Awad Ebrahim; Amr Medhat Abbas; Khaled Zalata; Maha Abo Hashim
Journal:  J Gastrointest Cancer       Date:  2012-03

2.  Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.

Authors:  Michael A Gordon; Wu Zhang; Dongyun Yang; Syma Iqbal; Anthony El-Khouiery; Fumio Nagashima; Georg Lurje; Melissa Labonte; Peter Wilson; Andy Sherrod; Robert D Ladner; Heinz-Josef Lenz
Journal:  Pharmacogenomics       Date:  2011-01       Impact factor: 2.533

3.  Associations between Environmental Exposures and Incident Colorectal Cancer by ESR2 Protein Expression Level in a Population-Based Cohort of Older Women.

Authors:  Lori S Tillmans; Robert A Vierkant; Alice H Wang; Niloy Jewel Samadder; Charles F Lynch; Kristin E Anderson; Amy J French; Robert W Haile; Lisa J Harnack; John D Potter; Susan L Slager; Thomas C Smyrk; Stephen N Thibodeau; James R Cerhan; Paul J Limburg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-02-03       Impact factor: 4.254

4.  Estrogen signaling in colorectal carcinoma microenvironment: expression of ERbeta1, AIB-1, and TIF-2 is upregulated in cancer-associated myofibroblasts and correlates with disease progression.

Authors:  Vassiliki Tzelepi; Petros Grivas; Zinovia Kefalopoulou; Haralabos Kalofonos; John N Varakis; Maria Melachrinou; Georgia Sotiropoulou-Bonikou
Journal:  Virchows Arch       Date:  2009-03-07       Impact factor: 4.064

5.  The cervical malignant cells display a down regulation of ER-α but retain the ER-β expression.

Authors:  Ricardo López-Romero; Efraín Garrido-Guerrero; Angélica Rangel-López; Leticia Manuel-Apolinar; Patricia Piña-Sánchez; Minerva Lazos-Ochoa; Alejandra Mantilla-Morales; Cindy Bandala; Mauricio Salcedo
Journal:  Int J Clin Exp Pathol       Date:  2013-07-15

6.  Expression and Prognostic Value of Oestrogen Receptor Beta in Colorectal Cancer.

Authors:  Elisabeth Pérez-Ruiz; Antonio Rueda; Lidia Pérez; Francisco Rivas-Ruiz; Esperanza Torres; Vanesa de Luque; Martina Álvarez; Isabel Sevilla; Maximino Redondo; Maria Padilla-Ruiz; Emilio Alba; Lorenzo Alonso
Journal:  Pathol Oncol Res       Date:  2017-09-09       Impact factor: 3.201

Review 7.  Estrogen receptor beta as target for colorectal cancer prevention.

Authors:  Cecilia Williams; Alfredo DiLeo; Yaron Niv; Jan-Åke Gustafsson
Journal:  Cancer Lett       Date:  2015-12-18       Impact factor: 8.679

8.  Chemopreventive efficacy of raloxifene, bexarotene, and their combination on the progression of chemically induced colon adenomas to adenocarcinomas in rats.

Authors:  Naveena B Janakiram; Altaf Mohammed; Yuting Zhang; Misty Brewer; Taylor Bryant; Stan Lightfoot; Vernon E Steele; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2013-09-30

9.  G protein-coupled receptor kinase 5 mediates Tazarotene-induced gene 1-induced growth suppression of human colon cancer cells.

Authors:  Chang-Chieh Wu; Fu-Ming Tsai; Rong-Yaun Shyu; Ya-Ming Tsai; Chun-Hua Wang; Shun-Yuan Jiang
Journal:  BMC Cancer       Date:  2011-05-17       Impact factor: 4.430

10.  Cyclin D1 expression in colorectal cancer is a favorable prognostic factor in men but not in women in a prospective, population-based cohort study.

Authors:  Sakarias Wangefjord; Jonas Manjer; Alexander Gaber; Björn Nodin; Jakob Eberhard; Karin Jirström
Journal:  Biol Sex Differ       Date:  2011-09-03       Impact factor: 5.027

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.